Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 4208-4212, September 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Du, W.
Right arrow Articles by Prendergast, G. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Du, W.
Right arrow Articles by Prendergast, G. C.
[Cancer Research 59, 4208-4212, September 1, 1999]
© 1999 American Association for Cancer Research

Advances in Brief

Activation of the PI3'K-AKT Pathway Masks the Proapoptotic Effects of Farnesyltransferase Inhibitors1

Wei Du2, Aixue Liu and George C. Prendergast3

The Wistar Institute, Philadelphia Pennsylvania 19104

Farnesyltransferase inhibitors (FTIs) usually cause growth inhibition, but in certain preclinical settings they have been shown to induce apoptosis, a clinically desirable response. In this study, we show that the proapoptotic effects of FTIs in Ras-transformed cells are masked by activation of phosphatidylinositol 3'-kinase (PI3'K) or AKT, which are controlled by cytokines and integrins. The results implied that FTIs disrupt a signal that is crucial for survival of malignant cells, but not normal cells, if the PI3'K-AKT pathway is inactivated. Our findings have implications for clinical applications of FTIs where apoptotic responses would be preferred.




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
S.-Y. Sun, X. Liu, W. Zou, P. Yue, A. I. Marcus, and F. R. Khuri
The Farnesyltransferase Inhibitor Lonafarnib Induces CCAAT/Enhancer-binding Protein Homologous Protein-dependent Expression of Death Receptor 5, Leading to Induction of Apoptosis in Human Cancer Cells
J. Biol. Chem., June 29, 2007; 282(26): 18800 - 18809.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Qiu, X. Liu, W. Zou, P. Yue, S. Lonial, F. R. Khuri, and S.-Y. Sun
The Farnesyltransferase Inhibitor R115777 Up-regulates the Expression of Death Receptor 5 and Enhances TRAIL-Induced Apoptosis in Human Lung Cancer Cells
Cancer Res., May 15, 2007; 67(10): 4973 - 4980.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Liu, R. Aneja, C. Liu, L. Sun, J. Gao, H. Wang, J.-T. Dong, V. Sarli, A. Giannis, H. C. Joshi, et al.
Inhibition of the Mitotic Kinesin Eg5 Up-regulates Hsp70 through the Phosphatidylinositol 3-Kinase/Akt Pathway in Multiple Myeloma Cells
J. Biol. Chem., June 30, 2006; 281(26): 18090 - 18097.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I.-A. Kim, S.-S. Bae, A. Fernandes, J. Wu, R. J. Muschel, W. G. McKenna, M. J. Birnbaum, and E. J. Bernhard
Selective Inhibition of Ras, Phosphoinositide 3 Kinase, and Akt Isoforms Increases the Radiosensitivity of Human Carcinoma Cell Lines
Cancer Res., September 1, 2005; 65(17): 7902 - 7910.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. Carloni, F. Vizzutti, and P. Pantaleo
Farnesyltransferase Inhibitor, ABT-100, Is a Potent Liver Cancer Chemopreventive Agent
Clin. Cancer Res., June 1, 2005; 11(11): 4266 - 4274.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Tabernero, F. Rojo, I. Marimon, M. Voi, J. Albanell, M. Guix, F. Vazquez, J. Carulla, M. Cooper, J. Andreu, et al.
Phase I Pharmacokinetic and Pharmacodynamic Study of Weekly 1-Hour and 24-Hour Infusion BMS-214662, a Farnesyltransferase Inhibitor, in Patients With Advanced Solid Tumors
J. Clin. Oncol., April 10, 2005; 23(11): 2521 - 2533.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Dai, M. Rahmani, X.-Y. Pei, P. Khanna, S. I. Han, C. Mitchell, P. Dent, and S. Grant
Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK
Blood, February 15, 2005; 105(4): 1706 - 1716.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. V. Heymach, D. H. Johnson, F. R. Khuri, H. Safran, L. L. Schlabach, F. Yunus, R. F. DeVore III, P. M. De Porre, H. M. Richards, X. Jia, et al.
Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer
Ann. Onc., August 1, 2004; 15(8): 1187 - 1193.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. Manne, F. Y. F. Lee, D. K. Bol, J. Gullo-Brown, C. R. Fairchild, L. J. Lombardo, R. A. Smykla, G. D. Vite, M.-L. D. Wen, C. Yu, et al.
Apoptotic and Cytostatic Farnesyltransferase Inhibitors Have Distinct Pharmacology and Efficacy Profiles in Tumor Models
Cancer Res., June 1, 2004; 64(11): 3974 - 3980.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. R. Khuri, B. S. Glisson, E. S. Kim, P. Statkevich, P. F. Thall, M. L. Meyers, R. S. Herbst, R. F. Munden, C. Tendler, Y. Zhu, et al.
Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors
Clin. Cancer Res., May 1, 2004; 10(9): 2968 - 2976.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Sun, J. Ohkanda, D. Coppola, H. Yin, M. Kothare, B. Busciglio, A. D. Hamilton, and S. M. Sebti
Geranylgeranyltransferase I Inhibitor GGTI-2154 Induces Breast Carcinoma Apoptosis and Tumor Regression in H-Ras Transgenic Mice
Cancer Res., December 15, 2003; 63(24): 8922 - 8929.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. M. Sebti
Blocked Pathways: FTIs Shut Down Oncogene Signals
Oncologist, December 1, 2003; 8(90003): 30 - 38.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. E. Lancet and J. E. Karp
Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy
Blood, December 1, 2003; 102(12): 3880 - 3889.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. R.D. Johnston, T. Hickish, P. Ellis, S. Houston, L. Kelland, M. Dowsett, J. Salter, B. Michiels, J. J. Perez-Ruixo, P. Palmer, et al.
Phase II Study of the Efficacy and Tolerability of Two Dosing Regimens of the Farnesyl Transferase Inhibitor, R115777, in Advanced Breast Cancer
J. Clin. Oncol., July 1, 2003; 21(13): 2492 - 2499.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Shi, J. Gera, J.-h. Hsu, B. Van Ness, and A. Lichtenstein
Cytoreductive Effects of Farnesyl Transferase Inhibitors on Multiple Myeloma Tumor Cells
Mol. Cancer Ther., June 1, 2003; 2(6): 563 - 572.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Hu, Y. Shi, J.-h. Hsu, J. Gera, B. Van Ness, and A. Lichtenstein
Downstream effectors of oncogenic ras in multiple myeloma cells
Blood, April 15, 2003; 101(8): 3126 - 3135.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. Mazzocca, S. Giusti, A. D. Hamilton, S. M. Sebti, P. Pantaleo, and V. Carloni
Growth Inhibition by the Farnesyltransferase Inhibitor FTI-277 Involves Bcl-2 Expression and Defective Association with Raf-1 in Liver Cancer Cell Lines
Mol. Pharmacol., January 1, 2003; 63(1): 159 - 166.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. R. D. Johnston, J. Head, S. Pancholi, S. Detre, L.-A. Martin, I. E. Smith, and M. Dowsett
Integration of Signal Transduction Inhibitors with Endocrine Therapy: An Approach to Overcoming Hormone Resistance in Breast Cancer
Clin. Cancer Res., January 1, 2003; 9(1): 524S - 532S.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. S. Clark, K. West, S. Streicher, and P. A. Dennis
Constitutive and Inducible Akt Activity Promotes Resistance to Chemotherapy, Trastuzumab, or Tamoxifen in Breast Cancer Cells
Mol. Cancer Ther., July 1, 2002; 1(9): 707 - 717.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. G. Ferreira, M. Epping, F. A. E. Kruyt, and G. Giaccone
Apoptosis: Target of Cancer Therapy
Clin. Cancer Res., July 1, 2002; 8(7): 2024 - 2034.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. L. van Golen, L. Bao, M. M. DiVito, Z. Wu, G. C. Prendergast, and S. D. Merajver
Reversion of RhoC GTPase-induced Inflammatory Breast Cancer Phenotype by Treatment with a Farnesyl Transferase Inhibitor
Mol. Cancer Ther., June 1, 2002; 1(8): 575 - 583.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. R. Kelland, V. Smith, M. Valenti, L. Patterson, P. A. Clarke, S. Detre, D. End, A. J. Howes, M. Dowsett, P. Workman, et al.
Preclinical Antitumor Activity and Pharmacodynamic Studies with the Farnesyl Protein Transferase Inhibitor R115777 in Human Breast Cancer
Clin. Cancer Res., November 1, 2001; 7(11): 3544 - 3550.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Pan, G. Xu, and S.-C. J. Yeung
Cytochrome c Release Is Upstream to Activation of Caspase-9, Caspase-8, and Caspase-3 in the Enhanced Apoptosis of Anaplastic Thyroid Cancer Cells Induced by Manumycin and Paclitaxel
J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4731 - 4740.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. C. Rose, F. Y. F. Lee, C. R. Fairchild, M. Lynch, T. Monticello, R. A. Kramer, and V. Manne
Preclinical Antitumor Activity of BMS-214662, a Highly Apoptotic and Novel Farnesyltransferase Inhibitor
Cancer Res., October 1, 2001; 61(20): 7507 - 7517.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. F. Gazdar and J. D. Minna
Targeted therapies for killing tumor cells
PNAS, August 28, 2001; 98(18): 10028 - 10030.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. A. Adjei
Blocking Oncogenic Ras Signaling for Cancer Therapy
J Natl Cancer Inst, July 18, 2001; 93(14): 1062 - 1074.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Pervin, R. Singh, C.-L. Gau, H. Edamatsu, F. Tamanoi, and G. Chaudhuri
Potentiation of Nitric Oxide-induced Apoptosis of MDA-MB-468 Cells by Farnesyltransferase Inhibitor: Implications in Breast Cancer
Cancer Res., June 1, 2001; 61(12): 4701 - 4706.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Gatzka, M. Prisco, and R. Baserga
Stabilization of the Ras Oncoprotein by the Insulin-like Growth Factor 1 Receptor during Anchorage-independent Growth
Cancer Res., August 1, 2000; 60(15): 4222 - 4230.
[Abstract] [Full Text]

Home page
 JCOHome page
E. K. Rowinsky, J. J. Windle, and D. D. Von Hoff
Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development
J. Clin. Oncol., November 1, 1999; 17(11): 3631 - 3652.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Du and G. C. Prendergast
Geranylgeranylated RhoB Mediates Suppression of Human Tumor Cell Growth by Farnesyltransferase Inhibitors
Cancer Res., November 1, 1999; 59(21): 5492 - 5496.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. M. Nelson and D. W. Fry
Akt, MAPK (Erk1/2), and p38 Act in Concert to Promote Apoptosis in Response to ErbB Receptor Family Inhibition
J. Biol. Chem., April 27, 2001; 276(18): 14842 - 14847.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.